Target Gene/Pathway Pathway / Gene


Search results


No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 MAPK14 [30] Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09639 Losmapimod [2] 113, 222
2 MAPK14 [30] Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10959 Neflamapimod [1] 8
3 IL1A [8] Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
4 IL1A [8] Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Rheumatoid arthritis D06635 Rilonacept [4] 51, 106, 107, 266
5 IL1A [8] Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Rheumatoid arthritis D11253 Bermekimab [1] 51
6 IL1B [15] Osteoclast differentiation, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
7 IL1B [15] Osteoclast differentiation, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D06635 Rilonacept [4] 51, 106, 107, 266
8 IL1B [15] Osteoclast differentiation, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D09315 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269
9 IL1B [15] Osteoclast differentiation, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis D09911 Gevokizumab [4] 41, 50, 56, 269
10 IL6 [16] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
11 IL6 [16] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D08976 Pomalidomide [6] 28, 34, 51, 85, 227, 331
12 IL6 [16] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D09669 Siltuximab [2] 28, 331
13 IL6 [16] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D10080 Sirukumab [2] 41, 46
14 IL6R [5] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer D02596 Tocilizumab [21] 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
15 IL6R [5] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer D10161 Sarilumab [5] 41, 46, 84, 107, 271
16 IL6R [5] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer D11079 Satralizumab [2] 11, 13
17 INSR [8] Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease D00085 Insulin human [2] 96, 156
18 INSR [8] Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease D03230 Insulin human [2] 96, 156
19 INSR [8] Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease D03250 Insulin glargine [1] 299
20 INSR [8] Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Non-alcoholic fatty liver disease D04539 Insulin detemir [1] 299
21 LEPR [1] Non-alcoholic fatty liver disease D05014 Metreleptin [1] 265
22 MAP3K5 [10] Platinum drug resistance, Sphingolipid signaling pathway, Protein processing in endoplasmic reticulum, Tight junction, TNF signaling pathway, Thermogenesis, Non-alcoholic fatty liver disease, Parkinson disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases D10988 Selonsertib [1] 86
23 NFKB1 [28] Ras signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D01146 Iguratimod [4] 46, 51, 53, 271
24 PIK3CA [36] Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11158 Leniolisib [2] 53, 65
25 PIK3CB [36] Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11158 Leniolisib [2] 53, 65
26 PIK3CD [36] Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11158 Leniolisib [2] 53, 65
27 PIK3CD [36] Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11437 Parsaclisib [3] 35, 53, 61
28 PPARA [2] PPAR signaling pathway, Non-alcoholic fatty liver disease D00565 Fenofibrate [5] 8, 79, 93, 94, 265
29 PPARA [2] PPAR signaling pathway, Non-alcoholic fatty liver disease D01366 Bezafibrate [7] 20, 93, 94, 160, 296, 316, 324
30 PPARA [2] PPAR signaling pathway, Non-alcoholic fatty liver disease D10711 Pemafibrate [1] 93
31 PPARA [2] PPAR signaling pathway, Non-alcoholic fatty liver disease D11208 Elafibranor [1] 93
32 PPARG [7] PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer D00596 Rosiglitazone [5] 46, 75, 97, 222, 265
33 PPARG [7] PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer D00945 Pioglitazone [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
34 PPARG [7] PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer D08378 Pioglitazone [17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
35 PPARG [7] PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer D08491 Rosiglitazone [5] 46, 75, 97, 222, 265
36 PPARG [7] PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer D11256 Seladelpar [2] 93, 94
37 PPARG [7] PPAR signaling pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer D11603 Leriglitazone [1] 20
38 PRKAA1 [5] PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease D00944 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
39 PRKAA1 [5] PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease D04966 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
40 PRKAA2 [5] PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease D00944 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
41 PRKAA2 [5] PI3K-Akt signaling pathway, Tight junction, Thermogenesis, Oxytocin signaling pathway, Non-alcoholic fatty liver disease D04966 Metformin [24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
42 MAPK11 [30] Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09639 Losmapimod [2] 113, 222
43 MAPK11 [30] Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10959 Neflamapimod [1] 8
44 MAPK13 [30] Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09639 Losmapimod [2] 113, 222
45 MAPK13 [30] Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10959 Neflamapimod [1] 8
46 RELA [28] Ras signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D12181 Edasalonexent [1] 113
47 RXRA [11] PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer D02754 Acitretin [1] 37
48 RXRA [11] PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer D02815 Alitretinoin [1] 49
49 RXRA [11] PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer D03106 Bexarotene [2] 13, 75
50 MAPK12 [30] Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09639 Losmapimod [2] 113, 222
51 MAPK12 [30] Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10959 Neflamapimod [1] 8
52 TGFB1 [12] TGF-beta signaling pathway, Osteoclast differentiation, Th17 cell differentiation, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Toxoplasmosis, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Rheumatoid arthritis D09620 Fresolimumab [4] 51, 85, 222, 274
53 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D00742 Etanercept [17] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
54 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D00754 Thalidomide [20] 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
55 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
56 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D02597 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271
57 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D02598 Infliximab [27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
58 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D03441 Certolizumab pegol [8] 37, 46, 49, 96, 97, 107, 226, 271
59 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04358 Golimumab [8] 46, 56, 84, 96, 97, 107, 270, 271
60 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04687 Lenalidomide [8] 16, 26, 28, 34, 49, 284, 300, 331
61 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D05393 Pegsunercept [1] 46
62 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D08976 Pomalidomide [6] 28, 34, 51, 85, 227, 331
63 TNF [23] Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D09944 Ozoralizumab [1] 46